Refractory Chronic Immune-mediated Demyelinating Polyneuropathy

Aziz Shaibani; Husam Al Sultani

doi:10.1016/j.ncl.2020.03.006

Refractory Chronic Immune-mediated Demyelinating Polyneuropathy

Neurol Clin. 2020 Aug;38(3):591-605. doi: 10.1016/j.ncl.2020.03.006. Epub 2020 Jun 11.

Authors

Aziz Shaibani¹, Husam Al Sultani²

Affiliations

¹ Nerve and Muscle Center of Texas, 6624 Fannin Street Suite 1670, Houston, TX 77030, USA; Baylor College of Medicine, Houston, TX, USA. Electronic address: ather@aol.com.
² Nerve and Muscle Center of Texas, 6624 Fannin Street Suite 1670, Houston, TX 77030, USA.

PMID: 32703471
DOI: 10.1016/j.ncl.2020.03.006

Abstract

Please verify term, "alternative". Chronic immune-mediated demyelinating polyneuropathy (CIDP) is a treatable immune-related demyelinating polyneuropathy. Approximately 20% of cases do not respond to first-line therapies; most of these cases are due to alternative diagnoses, although some of them are due to severe CIDP. Unfortunately, a lack of universally accepted diagnostic criteria complicates the course of diagnosis and treatment. This article discusses videos of cases referred to a tertiary medical center for "refractory CIDP" and pitfalls in the diagnosis and management of this condition.

Keywords: CIDP; Conduction block; Demyelinating; MAG antibodies; NF-155; Neuropathy; POEMS; Refractory.

Publication types

Case Reports
Review

MeSH terms

Adult
Aged
Female
Humans
Male
Middle Aged
Neural Conduction / physiology*
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / diagnosis*
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / physiopathology*
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / therapy